Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Bookmark and Share
Published: 30 Sep 2019
Views: 479
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Dr Enrique Grande presents data from the IMvigor130 trial during a press conference at the 2019 ESMO congress.

This was a trial evaluating first-line immunotherapy and chemotherapy instead of chemotherapy alone in patients with metastatic urothelial cancer.

Watch Dr Grande's interview with ecancer here.

Read more on the study here.